Moving forward with the IPO plans, Ujin Pharma Ltd. filed DRHP with SEBI on Jun 22, 2026. The proposed share sale offer will be a mix of a fresh issue of up to 1.19 crore equity shares and existing shareholders are planning to sell up to 0.73 crore shares.
SMC Capitals Ltd. is the Book Running Lead Manager for the IPO and Kfin Technologies Ltd. is the Registrar. The company’s shares will be listed on NSE and BSE.
According to the draft red herring prospectus, Not more than 50% of the Net Offer is reserved for Qualified Institutional Bidders (QIBs), Not less than 15% of the Net Offer for Non-Institutional Investors (NIIs) and Not less than 35% of the Net Offer for Retail Individual Investors (RIIs).
Financial Performance Overview
For financial year ending on Mar 31, 2025, the company’s total income stood at ₹1,636.06 crore, up 9% compared to ₹1,497.33 crore in Mar 31, 2024.
Profit after tax (PAT) stood at ₹14.29 crore, reflecting a decline of 10% from ₹16.01 crore a year ago.
For the period ended on Dec 31, 2025, the company reported total income of ₹1,523.11 crore and net profit of ₹25.47 crore.
